Symptom dimensional approach and BDNF in unmedicated obsessive-compulsive patients: An exploratory study

CNS Spectrums

Volumn 16, Issue 9, 2011, Pages 179-189

  dos Santos, Igor Marcanti ^a   Ciulla, Leandro ^a   Braga, Daniela ^b   Ceresér, Keila Maria ^b   Gama, Clarissa Severino ^b   Kapczinski, Flávio ^b   Ferrão, Ygor Arzeno ^c  

^a Federal University   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSION; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BODY DYSMORPHIC DISORDER; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIMENSIONAL YALE BROWN OBSESSIVE COMPULSIVE SCALE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; RELIGION; SEX; SKIN PICKING; SOCIAL PHOBIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 80053361852     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852912000363     Document Type: Article

References (66)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994.
2. WHO (World Health Organization. ICD-10: International Classification of Disorders and Health Related Problems, 10th ed. Porto Alegre: Artmed; 2007.
3. Torres AR, Prince MJ, Bebbington PE, et al. Obsessive-compulsive disorder: prevalence, comorbidity, impact and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psych. 2006;163(11):1978-1985.
4. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arc Gen Psychiatry. 1988;45(12):1094-1099.
5. Rosario-Campos MC, Leckman JF, et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001;158:1899-1903.
6. Diniz JB, Rosario-Campos MC, Shavitt RG, et al. Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. J Clin Psychiatry. 2004;65:22-27.
7. de Mathis MA, Rosário MC, Diniz JB, et al. Obsessive-compulsive disorder: influence of age at onset on comrbidity patterns. Eur Psychiatry. 2008;23(3):187-194.
8. Miguel EC, do Rosario-Campos MC, Prado HS, et al. Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. J Clin Psychiatry. 2000;61:150-156.
9. Miguel EC, Baer L, Coffey BJ, et al. Phenomenological differences appearing with repetitive behaviors in obsessive-compulsive. Br J Psychiatry. 1997;170:140-145.
10. Prado HS, Rosário MC, Lee J, et al. Sensory phenomena in obsessive-compulsive disorder and tic disorders: a review of the literature. CNS Spectr. 2008;13(5):425-432.
11. Nestadt G, Addington A, Samuels J, et al. The identification of OCD-related sub-groups based on comorbidity. Biol Psychiatry. 2003;53:914-920.
12. Leckman JF, Grice DE, Barr LC, et al. Tic-related vs. Non-tic-related obsessive-compulsive disorder. Anxiety. 1994;1:208-215.
13. Ferrão YA, Miguel EC, Stein DJ. Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: How closely are they related? Psychiatry Research. 2009;170(1):32-42.
14. Ravizza L, Maina G, Bogetto F. Episodic and chronic obsessive-compulsive disorder. Depress Anxiety. 1997;6:154-158.
15. Miguel EC, Rauch SL, Jenike MA. Obsessive-compulsive disorder. Psych Clin North Am. 1997;20(4):863-883.
16. Ferrão YA, Shavitt RG, Bedin NR, et al. Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord. 2006;94(1-3):199-209. Epub 2006 Jun 9.
17. Rosario-Campos MC, Miguel EC, Quatrano S, et al. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry. 2006;11(5):495-504.
18. Van den Heuvel OA, Remijnse PL, Mataix-Cols D, et al. The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain. 2009;132(Pt 4):853-868.
19. An SK, Mataix-Cols D, Lawrence NS, et al. To discard or not to discard: the neural basis of hoarding symptoms in obsessive-compulsive disorder. Mol Psychiatry. 2009;14(3):318-331.
20. Gilbert AR, Mataix-Cols D, Almeida JR, et al. Brain structure and symptom dimension relationships in obsessive-compulsive disorder: a voxel-based morphometry study. J Affect Disord. 2008;109(1-2):117-126.
21. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry. 2004;61(6):564-76.
22. Zahn R, Moll J, Paiva M, et al. The neural basis of human social values: evidence from functional MRI. Cereb Cortex. 2009;19(2):276-283.
23. Eslinger PJ, Robinson-Long M, Realmuto J, et al. Developmental frontal lobe imaging in moral judgment: Arthur Benton's enduring influence 60 years later. J Clin Exp Neuropsychol. 2009;31(2):158-169.
24. Kwon JS, Jang JH, Choi JS, Kang DH. Neuroimaging in obsessive-compulsive disorder. Expert Rev Neurother. 2009;9(2):255-269.
25. Maina G, Rosso G, Zanardini R, et al. Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: A case-control study. J Affect Disord. 2010;122(1-2):174-178.
26. Serrano-Sanchez T, Díaz-Armesto I. Factor de crecimiento derivado del cerebro: aspectos de actualidad. Rev Neurol. 1998;26:1027-1032.
27. Huang EJ, Reichardt LF. Neurotrophins: Roles in Neuronal Development and Function. Annu Rev Neurosci. 2001;24:677-736.
28. Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res. 2009; 43(14):1175-1184.
29. Carola V, Frazzetto G, Pascucci T, et al. Identifying molecular substrates in a mouse model of the serotonin transporter x environment risk factor for anxiety and depression. Biol Psychiatry. 2008;63(9):840-846.
30. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127.
31. Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet release unrelated to platelet reactivity. Biol Psychiatry. 2005;57:1068-1072.
32. Shimizu E, Hashimoto K, Okamura N, et al. Alterations on serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
33. Karege F, Ferret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-148.
34. Machado-Vieira R, Dietrich MO, Leke R, et al. Decreased Plasma Brain Derived Neurotrophic Factor Levels in Unmedicated Bipolar Patients During Manic Episode. Biol Psychiatry. 2007;61:142-144.
35. Tooyoka K, Asama K, Watanabe Y, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002;110:249-257.
36. Xiu MH, Hui L, Dang YF, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1508-1512.
37. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discovery Today. 2008;13(7/8):325-332.
38. Aouizerate B, Guehl D, Cuny E, et al. Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2005;1(3):231-243.
39. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360:397-405.
40. Daws LC, Munn JL, Valdez MF, Frosto-Burke T, Hensler JG. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J Neurochem. 2007;101(3):641-651.
41. Mössner R, Daniel S, Albert D, et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int. 2000;36(3):197-202.
42. Katerberg H, Lochner C, Cath DC, et al. The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). Am J Med Genet B Neuropsychiatr Genet. 2009;150B(8):1050-1062.
43. Dickel DE, Veenstra-Van derWeele J, Bivens NC, et al. Association Studies of Serotonin System Candidate Genes in Early-onset Obsessive-Compulsive Disorder. Biol Psychiatry. 2007;61:322-329.
44. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Sequence Variants of the Brain-Derived Neurotrophic Factor (BDNF) Gene Are Strongly Associated with Obsessive-Compulsive Disorder. Am J Hum Genet. 2003;73:370-376.
45. Mössner R, Walitza S, Lesch KP, et al. Brain-derived neurotrophic factor V66M polymorphism in childhood-onset obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8(1):133-136.
46. Zai G, Arnold P, Strauss J, et al. No association between brain-derived neurotrophic factor gene and obsessive-compulsive disorder. Psychiatr Genet. 2005;15(4):235.
47. Alonso P, Gratacòs M, Menchón JM, et al. Extensive Genotyping of the BDNF and NTRK2 Genes Define Protective Haplotypes Against Obsessive-Compulsive Disorder. Biol Psychiatry. 2008;63:619-628.
48. Hemmings SM, Kinnear CJ, Van der Merwe L, et al. Investigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD). World J Biol Psychiatry. 2008;9(2):126-134.
49. Wendland JR, Kruse MR, Cromer KR, Murphy DL. A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. Neuropsychopharmacology. 2007;32(12):2543-2551.
50. Miguel EC, Ferrão YA, Rosário MC, et al. The Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev Bras Psiquiatr. 2008;30(3):185-196.
51. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders: clinical version (SCID-CV). Washington, DC: American Psychiatric Press, 1997.
52. First MB. Structural clinical interview for DSM-IV-TR Impulse Control Disorders Not Elsewhere Classified (SCID-TCIm). Biometrics Research Department; New York State Psychiatric Institute, 2004.
53. Goodman WK, Price LH, Rasmussen SA. The Yale Brown Obsessive Compulsive Scale YBOCS Part I Development, Use and Reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
54. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh G. An Inventory for Measuring Depression. Arch Gen Psychiatry. 1961;4:53-63.
55. Beck AT, Brown G, Epstein N, Steer RA. An Inventory for Measuring Clinical Anxiety. J Consult Clin Psychol. 1988;56:893-897.
56. Trajkovska V, Marcussen AB, Vinberg M, et al. Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. Brain Res Bull. 2007;73:143-149.
57. Araya AV, Orellana X, Espinoza J. Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine. 2008;33(3):300-304.
58. Shugart YY, Chen L, Day IN, et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet. 2009;17(8):1050-1055.
59. Real E, Gratacòs M, Soria V, et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol Psychiatry. 2009;66(7):674-680.
60. Balu DT, Hoshaw BA, Malberg JE, et al. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008;1211:37-43.
61. Sen S, Duman R, Sanacora G. Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. Biol Psychiatry. 2008;64(6):527-532.
62. Masi G, Millepiedi S, Perugi G, et al. A naturalistic exploratory study of the impact of demographic, phenotypic and comorbid features in pediatric obsessive-compulsive disorder. Psychopathology. 2010;43(2):69-78.
63. Fullana MA, Mataix-Cols D, Caspi A, et al. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am J Psychiatry. 2009;166(3):329-336.
64. Hantouche EG, Angst J, Demonfaucon C, et al. Cyclothymic OCD: a distinct form? J Affect Disord. 2003;75(1):1-10.
65. Pinto A, Eisen JL, Mancebo MC, et al. Taboo thoughts and doubt/checking: a refinement of the factor structure for obsessive-compulsive disorder symptoms. Psychiatry Res. 2007;151(3):255-258.
66. Pinto A, Greenberg BD, Grados MA, et al. Further development of YBOCS dimensions in the OCD Collaborative Genetics study: symptoms vs. categories. Psychiatry Res. 2008;160(1):83-93.